Home › Encyclopedia › PT-141 (Bremelanotide): Research Status and Trial Data
Research / Unapproved

PT-141 (Bremelanotide): Research Status and Trial Data

Molecular formulaC50H68N14O10
Molecular weight1025.2 g/mol
Registered trials4
PubChem CID9941379

What PT-141 is

PT-141, also known as bremelanotide, is a synthetic peptide compound with the molecular formula C50H68N14O10 and a molecular weight of approximately 1025.2 g/mol (PubChem CID 9941379). It does not currently carry an FDA-approved label under the name PT-141, and no indications, mechanism text, or brand names are available from label sources for this entry. It is classified in research and regulatory databases as an investigational compound, and nothing in this summary should be read as a statement of safety or effectiveness.

Trial footprint

Public registries list 4 trials associated with this compound. Among the sampled studies, one completed Phase 2 trial evaluated bremelanotide in women with female sexual arousal disorder (NCT00425256). A completed Phase 3 trial examined bremelanotide in premenopausal women with hypoactive sexual desire disorder (NCT02338960), and a separate completed Phase 2 trial covered both female sexual arousal disorder and hypoactive sexual desire disorder (NCT01382719). These listings describe study design and status only, not conclusions about outcomes.

FAQ

Is PT-141 FDA approved?
This entry reflects PT-141 as an unapproved, investigational compound, with no FDA label data available under this name. Regulatory status can vary by country and by the specific product name used, so always check current sources.
What is PT-141 made of?
PT-141 is a synthetic peptide with the molecular formula C50H68N14O10 and a molecular weight of about 1025.2 g/mol. It is cataloged in PubChem under CID 9941379.
How many clinical trials have studied PT-141?
Public registries show 4 trials associated with this compound. Sampled studies include completed Phase 2 and Phase 3 trials focused on female sexual arousal disorder and hypoactive sexual desire disorder.
What were the sample trials studying?
The sampled trials evaluated bremelanotide, the compound also known as PT-141, in premenopausal and other women with female sexual arousal disorder or hypoactive sexual desire disorder. All three sampled trials are listed as completed.
Are there reported side effects for PT-141 in this data?
No adverse event report data was available for this entry, so no side effect summary can be provided here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 9941379 ClinicalTrials.gov

Updated 2026-11-07